SE9903028D0 - New use - Google Patents

New use

Info

Publication number
SE9903028D0
SE9903028D0 SE9903028A SE9903028A SE9903028D0 SE 9903028 D0 SE9903028 D0 SE 9903028D0 SE 9903028 A SE9903028 A SE 9903028A SE 9903028 A SE9903028 A SE 9903028A SE 9903028 D0 SE9903028 D0 SE 9903028D0
Authority
SE
Sweden
Prior art keywords
chf
stroke
diabetes
heart failure
congestive heart
Prior art date
Application number
SE9903028A
Other languages
English (en)
Inventor
Gilles Dagenais
Hertzel Gerstein
Anders Ljunggren
Salim Yusuf
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20416770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9903028(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9903028A priority Critical patent/SE9903028D0/sv
Publication of SE9903028D0 publication Critical patent/SE9903028D0/sv
Priority to EP04006330A priority patent/EP1437131B1/en
Priority to SI200031069T priority patent/SI1437131T1/sl
Priority to EP10010670A priority patent/EP2277519A3/en
Priority to SI200031084T priority patent/SI1925303T1/sl
Priority to PCT/EP2000/008341 priority patent/WO2001015673A2/en
Priority to EEP200200085A priority patent/EE05130B1/xx
Priority to CNA2008101259535A priority patent/CN101537181A/zh
Priority to MXPA02001633A priority patent/MXPA02001633A/es
Priority to TR2002/02464T priority patent/TR200202464T2/xx
Priority to TR2002/02463T priority patent/TR200202463T2/xx
Priority to ES00965898.0T priority patent/ES2250192T5/es
Priority to TR2002/02466T priority patent/TR200202466T2/xx
Priority to ES08004265.8T priority patent/ES2525699T3/es
Priority to EP00965898.0A priority patent/EP1212081B2/en
Priority to DK08004265.8T priority patent/DK1925303T3/en
Priority to AU76484/00A priority patent/AU7648400A/en
Priority to AT04006330T priority patent/ATE554761T1/de
Priority to KR1020087007837A priority patent/KR20080035703A/ko
Priority to UA2002032397A priority patent/UA76702C2/uk
Priority to EP08004265.8A priority patent/EP1925303B1/en
Priority to PT04006330T priority patent/PT1437131E/pt
Priority to DK04006330.7T priority patent/DK1437131T3/da
Priority to TR2002/02467T priority patent/TR200202467T2/xx
Priority to CZ20020644A priority patent/CZ303433B6/cs
Priority to KR1020027002521A priority patent/KR20020060167A/ko
Priority to IL148126A priority patent/IL148126A/en
Priority to ES04006330T priority patent/ES2386141T3/es
Priority to TR2002/00518T priority patent/TR200200518T2/xx
Priority to DE60023518.1T priority patent/DE60023518T3/de
Priority to SK270-2002A priority patent/SK288239B6/sk
Priority to MEP-282/08A priority patent/MEP28208A/xx
Priority to NZ571901A priority patent/NZ571901A/en
Priority to HU0202461A priority patent/HU229107B1/hu
Priority to RU2002107673/15A priority patent/RU2272651C2/ru
Priority to CA002382387A priority patent/CA2382387C/en
Priority to JP2001519887A priority patent/JP4843172B2/ja
Priority to SI200030766T priority patent/SI1212081T2/sl
Priority to PL00353066A priority patent/PL353066A1/xx
Priority to BR0013540-2A priority patent/BR0013540A/pt
Priority to DK00965898.0T priority patent/DK1212081T4/da
Priority to AT00965898T priority patent/ATE307604T1/de
Priority to CNB008110700A priority patent/CN100408093C/zh
Priority to PT80042658T priority patent/PT1925303E/pt
Priority to RS3602A priority patent/RS52907B/en
Priority to YU3602A priority patent/YU3602A/sh
Priority to BG106319A priority patent/BG66115B1/bg
Priority to BG11047909A priority patent/BG110479A/bg
Priority to ZA200201471A priority patent/ZA200201471B/xx
Priority to NO20020850A priority patent/NO329245B1/no
Priority to HR20020169A priority patent/HRP20020169A2/hr
Priority to HK03102600.5A priority patent/HK1050327A1/xx
Priority to AU2005203694A priority patent/AU2005203694A1/en
Priority to RU2005128124/15A priority patent/RU2378018C2/ru
Priority to UAA200601774A priority patent/UA88270C2/ru
Priority to US11/415,137 priority patent/US20060194868A1/en
Priority to US12/027,938 priority patent/US20080125472A1/en
Priority to AU2009200551A priority patent/AU2009200551B2/en
Priority to US12/457,589 priority patent/US20090258919A1/en
Priority to US12/615,588 priority patent/US20100267798A1/en
Priority to NO20100569A priority patent/NO20100569L/no
Priority to US12/957,777 priority patent/US20110263619A1/en
Priority to CY20121100657T priority patent/CY1112987T1/el
Priority to US13/673,852 priority patent/US20130317047A1/en
Priority to CY20141101082T priority patent/CY1115869T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
SE9903028A 1999-08-27 1999-08-27 New use SE9903028D0 (sv)

Priority Applications (65)

Application Number Priority Date Filing Date Title
SE9903028A SE9903028D0 (sv) 1999-08-27 1999-08-27 New use
EP04006330A EP1437131B1 (en) 1999-08-27 2000-08-25 Use of ramipril for the prevention of diabetes in a patient with no preexisting congestive heart failure
SI200031069T SI1437131T1 (sl) 1999-08-27 2000-08-25 Uporaba ramiprila za preprečevanje diabetesa pri bolniku brez predhodno obstoječe kongestivne srčne opovedi
EP10010670A EP2277519A3 (en) 1999-08-27 2000-08-25 Use of Angiotensin II type 1 receptor antagonists for the prevention of stroke, diabetes and/or congestive heart failure
SI200031084T SI1925303T1 (sl) 1999-08-27 2000-08-25 Uporaba angiotenzin II tip 1 receptorskih antagonistov za preprečevanje diabetesa
PCT/EP2000/008341 WO2001015673A2 (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
EEP200200085A EE05130B1 (et) 1999-08-27 2000-08-25 Angiotensiini konvertaasi inhibiitori kasutamine ravimina kongestiivse sdamepuudulikkuse „rahoidmiseks
CNA2008101259535A CN101537181A (zh) 1999-08-27 2000-08-25 药物制剂及其在预防中风、糖尿病和/或充血性心衰中的应用
MXPA02001633A MXPA02001633A (es) 1999-08-27 2000-08-25 Formulaciones farmaceuticas y su uso en la prevencion de ataque, diabetes y/o falla cardiaca congestiva.
TR2002/02464T TR200202464T2 (tr) 1999-08-27 2000-08-25 Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formülasyonlar
TR2002/02463T TR200202463T2 (tr) 1999-08-27 2000-08-25 Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formülasyonlar
ES00965898.0T ES2250192T5 (es) 1999-08-27 2000-08-25 Uso de ramipril en la prevención de la insuficiencia cardiaca congestiva
TR2002/02466T TR200202466T2 (tr) 1999-08-27 2000-08-25 Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formülasyonlar.
ES08004265.8T ES2525699T3 (es) 1999-08-27 2000-08-25 Uso de antagonistas del receptor de tipo 1 de la angiotensina II para la prevención de diabetes
EP00965898.0A EP1212081B2 (en) 1999-08-27 2000-08-25 Use of ramipril in the prevention of congestive heart failure
DK08004265.8T DK1925303T3 (en) 1999-08-27 2000-08-25 Use of the angiotensin II type 1 receptor antagonists for the prevention of diabetes
AU76484/00A AU7648400A (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
AT04006330T ATE554761T1 (de) 1999-08-27 2000-08-25 Verwendung von ramipril zur vorbeugung von diabetes bei einem patienten ohne bestehendes kongestives herzversagen
KR1020087007837A KR20080035703A (ko) 1999-08-27 2000-08-25 뇌졸중, 당뇨병 및/또는 울혈성 심부전증 예방용 약제학적조성물
UA2002032397A UA76702C2 (uk) 1999-08-27 2000-08-25 Застосування раміприлу для запобігання розвитку застійної серцевої недостатності
EP08004265.8A EP1925303B1 (en) 1999-08-27 2000-08-25 Use of Angiotensin II type 1 receptor antagonists for the prevention of diabetes
PT04006330T PT1437131E (pt) 1999-08-27 2000-08-25 Utilização de ramipril para a prevenção de diabetes num doente sem insuficiência cardíaca congestiva pré-existente
DK04006330.7T DK1437131T3 (da) 1999-08-27 2000-08-25 Anvendelse af ramipril til forebyggelse af diabetes hos en patient uden præeksisterende kongestiv hjerteinsufficiens
TR2002/02467T TR200202467T2 (tr) 1999-08-27 2000-08-25 Felç, diyabet ve/veya konjesif kalp yetmezliğinin önlenmesinde kullanılan farmakolojik formulasyonlar
CZ20020644A CZ303433B6 (cs) 1999-08-27 2000-08-25 Použití ramiprilu, ramiprilátu nebo jejich farmaceuticky prijatelných derivátu
KR1020027002521A KR20020060167A (ko) 1999-08-27 2000-08-25 뇌졸중, 당뇨병 및/또는 울혈성 심부전증의 예방을 위한약제학적 제형 및 이의 용도
IL148126A IL148126A (en) 1999-08-27 2000-08-25 Use of Rampril or Ramiprilat or their pharmaceutical salt preparation to prepare a heart failure medication in patients without previous heart failure
ES04006330T ES2386141T3 (es) 1999-08-27 2000-08-25 Uso de ramipril para la prevención de diabetes en un paciente sin insuficiencia cardíaca congestiva preexistente
TR2002/00518T TR200200518T2 (tr) 1999-08-27 2000-08-25 Felç, Diyabet ve/veya Konjesif Kalp Yetmezliğinin Önlenmesinde Kullanılan Farmolojik Formulasyonlar
DE60023518.1T DE60023518T3 (de) 1999-08-27 2000-08-25 Verwendung von ramipril zur prophylaxe von kongestivem herzversagen
SK270-2002A SK288239B6 (sk) 1999-08-27 2000-08-25 Použitie ramiprilu na výrobu liečiva na prevenciu kongestívneho zlyhania srdca
MEP-282/08A MEP28208A (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
NZ571901A NZ571901A (en) 1999-08-27 2000-08-25 Use of ramipril or ramiprilat for the prevention of congestive heart failure
HU0202461A HU229107B1 (en) 1999-08-27 2000-08-25 Use of ramipril in prevention of congestive heart failure
RU2002107673/15A RU2272651C2 (ru) 1999-08-27 2000-08-25 Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности
CA002382387A CA2382387C (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
JP2001519887A JP4843172B2 (ja) 1999-08-27 2000-08-25 医薬処方物および卒中、糖尿病および／またはうっ血性心不全の予防におけるその使用
SI200030766T SI1212081T2 (sl) 1999-08-27 2000-08-25 Uporaba ramiprila za preprečevanje kongestivne srčne odpovedi
PL00353066A PL353066A1 (en) 1999-08-27 2000-08-25 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
BR0013540-2A BR0013540A (pt) 1999-08-27 2000-08-25 Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva
DK00965898.0T DK1212081T4 (da) 1999-08-27 2000-08-25 Anvendelse af ACE-inhibitorer i forebyggelse af kongestivt hjertesvigt
AT00965898T ATE307604T1 (de) 1999-08-27 2000-08-25 Verwendung von ace inhibitoren zur prophylaxe von kongestivem herzversagen
CNB008110700A CN100408093C (zh) 1999-08-27 2000-08-25 血管紧张素转化酶抑制剂在制备预防或降低充血性心衰的药物中的用途
PT80042658T PT1925303E (pt) 1999-08-27 2000-08-25 Utilização de antagonistas do receptor tipo 1 da angiotensina ii para a prevenção de diabetes
RS3602A RS52907B (en) 1999-08-27 2000-08-25 USE OF ACE INHIBITORS FOR THE PREVENTION OF CONGESTIVE HEART INSUFFICIENCY
YU3602A YU3602A (sh) 1999-08-27 2002-01-16 Farmaceutske formulacije inhibitora renin-angiotenzin sistema (ras) i njihova primena
BG106319A BG66115B1 (bg) 1999-08-27 2002-01-18 Използване на рамиприл или негова фармацевтично приемлива сол за предотвратяване на конгестивна сърдечна недостатъчност
BG11047909A BG110479A (en) 1999-08-27 2002-01-18 Pharmaceutical preparations and their use in the prevention of stroke, diabetes and/or congestive heart failure
ZA200201471A ZA200201471B (en) 1999-08-27 2002-02-21 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure.
NO20020850A NO329245B1 (no) 1999-08-27 2002-02-21 Anvendelse av ramipril eller ramiprilat for fremstilling av medikament
HR20020169A HRP20020169A2 (en) 1999-08-27 2002-02-26 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
HK03102600.5A HK1050327A1 (en) 1999-08-27 2003-04-10 Use of an angiotensin converting enzyme inhibitor in the manufacture of a medicament for the prevention or reduction of the risk of congestive heart failure
AU2005203694A AU2005203694A1 (en) 1999-08-27 2005-08-17 Pharmaceutical Formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
RU2005128124/15A RU2378018C2 (ru) 1999-08-27 2005-09-08 Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности
UAA200601774A UA88270C2 (ru) 1999-08-27 2006-02-20 Фармацевтический препарат и его применение для профилактики удара, диабета
US11/415,137 US20060194868A1 (en) 1999-08-27 2006-05-02 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and /or congestive heart failure
US12/027,938 US20080125472A1 (en) 1999-08-27 2008-02-07 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
AU2009200551A AU2009200551B2 (en) 1999-08-27 2009-02-12 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
US12/457,589 US20090258919A1 (en) 1999-08-27 2009-06-16 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and / or congestive heart failure
US12/615,588 US20100267798A1 (en) 1999-08-27 2009-11-10 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
NO20100569A NO20100569L (no) 1999-08-27 2010-04-20 Farmasoytiske formuleringer og anvendelse derav i forebyggelsen av slag, diabetes og/eller kongestivt hjertesvikt
US12/957,777 US20110263619A1 (en) 1999-08-27 2010-12-01 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
CY20121100657T CY1112987T1 (el) 1999-08-27 2012-07-24 Χρηση της ραμιπριλης για την προληψη του διαβητη σε ασθενη χωρις προυπαρχουσα συμφορητικη καρδιακη ανεπαρκεια
US13/673,852 US20130317047A1 (en) 1999-08-27 2012-11-09 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
CY20141101082T CY1115869T1 (el) 1999-08-27 2014-12-23 Χρηση ανταγωνιστων του υποδοχεα τυπου 1 της αγγειοτενσινης ii για την προληψη του διαβητη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903028A SE9903028D0 (sv) 1999-08-27 1999-08-27 New use

Publications (1)

Publication Number Publication Date
SE9903028D0 true SE9903028D0 (sv) 1999-08-27

Family

ID=20416770

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903028A SE9903028D0 (sv) 1999-08-27 1999-08-27 New use

Country Status (36)

Country Link
US (6) US20060194868A1 (sv)
EP (4) EP2277519A3 (sv)
JP (1) JP4843172B2 (sv)
KR (2) KR20080035703A (sv)
CN (2) CN101537181A (sv)
AT (2) ATE554761T1 (sv)
AU (3) AU7648400A (sv)
BG (2) BG110479A (sv)
BR (1) BR0013540A (sv)
CA (1) CA2382387C (sv)
CY (2) CY1112987T1 (sv)
CZ (1) CZ303433B6 (sv)
DE (1) DE60023518T3 (sv)
DK (3) DK1212081T4 (sv)
EE (1) EE05130B1 (sv)
ES (3) ES2525699T3 (sv)
HK (1) HK1050327A1 (sv)
HR (1) HRP20020169A2 (sv)
HU (1) HU229107B1 (sv)
IL (1) IL148126A (sv)
ME (1) MEP28208A (sv)
MX (1) MXPA02001633A (sv)
NO (2) NO329245B1 (sv)
NZ (1) NZ571901A (sv)
PL (1) PL353066A1 (sv)
PT (2) PT1925303E (sv)
RS (1) RS52907B (sv)
RU (2) RU2272651C2 (sv)
SE (1) SE9903028D0 (sv)
SI (3) SI1925303T1 (sv)
SK (1) SK288239B6 (sv)
TR (5) TR200202464T2 (sv)
UA (2) UA76702C2 (sv)
WO (1) WO2001015673A2 (sv)
YU (1) YU3602A (sv)
ZA (1) ZA200201471B (sv)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2276997C2 (ru) * 1999-08-30 2006-05-27 Санофи-Авентис Дойчланд Гмбх Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
US6903111B2 (en) 2001-03-26 2005-06-07 Kotobuki Pharmaceutical Co., Ltd. Isoquinuclidine derivative process for producing the same, and medicinal composition containing the same
EP1438043A2 (en) * 2001-10-17 2004-07-21 Aventis Pharma Deutschland GmbH Method of reducing type 2 diabetes in high risk patients
US6844361B2 (en) 2002-02-04 2005-01-18 Aventis Pharma Deutschland Gmbh Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
WO2004080482A2 (en) * 2003-03-11 2004-09-23 Institut De Cardiologie De Montréal / Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure
NZ543109A (en) 2003-04-25 2008-06-30 Novacardia Inc Method of improved diuresis in individuals with impaired renal function
PL1687006T3 (pl) * 2003-11-18 2008-01-31 Solvay Pharm Gmbh Kompozycje farmaceutyczne do leczenia zaburzeń czynności nerek
NZ586285A (en) * 2004-03-17 2011-12-22 Novartis Ag Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
RU2007120817A (ru) * 2004-11-05 2008-12-10 Кинг Фармасьютикалз Рисерч Энд Дивелопмент Стабилизированные покрытие по отдельности частицы рамиприла, композиции и способы
EP1948183B1 (en) * 2005-10-13 2013-12-18 Duke University Compositions for the treatment and prevention of heart disease and methods of using same
CA2661598A1 (en) * 2006-08-28 2008-03-06 Sanofi-Aventis Deutschland Gmbh Methods of lowering glucose levels
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
WO2009134383A2 (en) 2008-05-01 2009-11-05 Complexa Inc. Vinyl substituted fatty acids
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US8338565B2 (en) 2008-08-20 2012-12-25 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of tumor necrosis factor alpha
EP2459189A4 (en) 2009-07-31 2013-01-16 Univ Pittsburgh FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
US8686167B2 (en) 2009-10-02 2014-04-01 Complexa, Inc. Heteroatom containing substituted fatty acids
KR101431368B1 (ko) 2010-05-14 2014-08-19 사반치 유니버시티 의학적 치료에서 유체역학적 캐비테이션을 이용하는 장치
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
WO2016176338A1 (en) * 2015-04-30 2016-11-03 The Trustees Of Columbia University In The City Of New York Small molecule ras ligands
IL280619B2 (en) 2015-07-07 2023-10-01 H Lundbeck As Phosphodiesterase 9 inhibitors with an imidazo triazinon or imidazo pyrazinone skeleton for the treatment of peripheral diseases
EP3355879A4 (en) 2015-10-02 2019-05-22 Complexa, Inc. PREVENTION, TREATMENT AND INVERSION OF DISEASE USING THERAPEUTICALLY EFFECTIVE AMOUNTS OF ACTIVATED FATTY ACIDS
CN110833620A (zh) * 2018-08-15 2020-02-25 王镕 血管紧张素转化酶抑制剂在防治自身免疫性疾病及相应的并发症中的用途
KR20230137654A (ko) * 2022-03-22 2023-10-05 주식회사 메디포럼 뇌졸중의 예방 및 치료용 조성물

Family Cites Families (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (sv) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US5684016A (en) * 1984-04-12 1997-11-04 Hoechst Aktiengesellschaft Method of treating cardiac insufficiency
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
US5231080A (en) * 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
EP0241201A3 (en) * 1986-04-07 1990-05-23 Merck & Co. Inc. Angiotensin converting enzyme inhibitors useful in prolonging survival of mammalians with congestive heart failure
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
DE3704661A1 (de) 1987-02-14 1988-08-25 Hoechst Ag Annelierte azepinon- und azocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
EP0331014A3 (de) * 1988-03-02 1991-10-23 THERA - Patent Verwaltungs-GmbH Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe
US5217958A (en) * 1988-03-03 1993-06-08 E. R. Squibb & Sons, Inc. 1,2-hydroxy phosphonates and derivatives thereof
US4804770A (en) * 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3818245A1 (de) * 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
EP0444156A4 (en) * 1988-11-21 1992-12-09 Abbott Laboratories Method for treating vascular diseases
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
IL94390A (en) 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
ATE190051T1 (de) 1989-06-14 2000-03-15 Smithkline Beecham Corp Imidazoalkensäure
CA2018443A1 (en) 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
JP2550442B2 (ja) 1989-06-30 1996-11-06 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー 置換イミダゾール
HU215834B (hu) 1989-06-30 1999-04-28 E. I. Du Pont De Nemours And Co. Eljárás aromás csoporttal szubsztituált imidazolszármazékok, valamint ezeket hatóanyagként tartalmazó gyógyszerkészítmények előállítására
CA2020073A1 (en) 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
US5164407A (en) 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
FI94339C (sv) * 1989-07-21 1995-08-25 Warner Lambert Co Förfarande för framställning av farmaceutiskt användbar /R-(R*,R*)/-2-(4-fluorfenyl)- , -dihydroxi-5-(1-metyletyl)-3-fenyl-4-/(fenylamino)karbonyl/-1H-pyrrol-1-heptansyra och farmaceutiskt användbara salter därav
EP0412594B1 (en) 1989-07-28 1996-01-03 Merck & Co. Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
DE69013607T2 (de) 1989-08-02 1995-03-02 Takeda Chemical Industries Ltd Pyrazol-Derivate, Verfahren zu deren Herstellung und Anwendung.
FI903966A0 (fi) 1989-08-11 1990-08-10 Ici Plc Kvaevefoereningar.
DE3926606A1 (de) * 1989-08-11 1991-02-14 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
US5100897A (en) 1989-08-28 1992-03-31 Merck & Co., Inc. Substituted pyrimidinones as angiotensin ii antagonists
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
EP0424317A3 (en) 1989-10-19 1991-09-25 Ciba-Geigy Ag Pyrimidines
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
US5212165A (en) * 1989-10-23 1993-05-18 E. R. Squibb & Sons, Inc. Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
AU640417B2 (en) 1989-10-25 1993-08-26 Smithkline Beecham Corporation Substituted 5-((tetrazolyl)alkenyl)imidazoles
CA2026686A1 (en) * 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
IL96019A0 (en) 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
CA2028925A1 (en) 1989-11-06 1991-05-07 Gerald R. Girard Substituted n-(imidazolyl)alkyl alanine derivatives
PT95899A (pt) 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
IE903911A1 (en) 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
US5073566A (en) 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
JPH03223281A (ja) 1989-12-01 1991-10-02 Glaxo Group Ltd ベンゾチオフェン誘導体
EP0430300A3 (en) 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
GB8927277D0 (en) 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5104891A (en) 1989-12-11 1992-04-14 G. D. Searle & Co. Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension
EP0434038A1 (en) 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
EP0435827A3 (en) 1989-12-28 1991-11-13 Ciba-Geigy Ag Diaza compounds
CA2032289A1 (en) 1989-12-29 1991-06-30 Joseph A. Finkelstein Substituted 5-(alkyl) carboxamide imidazoles
CA2075621A1 (en) 1990-02-13 1991-08-14 William J. Greenlee Imidazole angiotensin ii antagonists incorporating a substituted benzyl element
WO1991011999A1 (en) 1990-02-13 1991-08-22 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
JP2726563B2 (ja) 1990-02-13 1998-03-11 メルク・エンド・カムパニー・インコーポレーテツド 置換ベンジル要素を含むトリアゾールアンギオテンシン▲ｉｉ▼拮抗物質
WO1991012696A1 (de) 1990-02-14 1991-08-22 Siemens Aktiengesellschaft Verfahren zur demodulation von secam-codierten farbfernsehsignalen mit zeilenverkoppeltem takt und schaltungsanordnung zur durchführung des verfahrens
US5162326A (en) 1990-02-15 1992-11-10 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
IL97219A (en) 1990-02-19 1995-12-08 Ciba Geigy Ag Elliptical amino compounds converted by biphenyl process for their preparation and pharmaceutical preparations containing them
CA2036618C (en) 1990-02-22 2002-10-29 Akira Morimoto Fused thiophene derivatives, their production and use
DE4006693A1 (de) 1990-03-01 1991-09-05 Schering Ag Neue benzimidazolderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US5044166A (en) 1990-03-05 1991-09-03 Membrane Technology & Research, Inc. Refrigeration process with purge and recovery of refrigerant
CA2037630C (en) 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
GB9005354D0 (en) 1990-03-09 1990-05-02 Glaxo Group Ltd Chemical compounds
FR2659655B1 (fr) 1990-03-19 1992-07-24 Union Pharma Scient Appl Nouveaux derives d'oxypyrazole antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5223516A (en) 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
EP0523141A4 (en) 1990-03-30 1993-04-21 Merck & Co. Inc. Substituted pyrazoles, isoxazoles and isothiazoles
EP0522038A4 (en) 1990-03-30 1993-05-26 Merck & Co. Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
DE4010797A1 (de) 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
CA2077897A1 (en) 1990-04-13 1991-10-14 Robert G. Franz Substituted benzimidazoles
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
EP0453210A3 (en) 1990-04-19 1993-01-13 Imperial Chemical Industries Plc Pyridine derivatives
US5703110A (en) 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5098920A (en) 1990-05-04 1992-03-24 G. D. Searle & Co. 1h-substituted-1,2,4-triazole compounds and methods of use thereof for treatment of cardiovascular disorders
GB9010394D0 (en) 1990-05-09 1990-06-27 Ici Plc Heterocyclic compounds
CA2041763A1 (en) 1990-05-11 1991-11-12 Sheih-Shung T. Chen Microbial transformation process for antihypertensive products
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
JPH05506443A (ja) 1990-05-25 1993-09-22 ジー．ディー．サール　アンド　カンパニー 心臓血管障害の治療用ｎ―置換１，２，４―トリアゾロン化合物
US5166143A (en) * 1990-05-31 1992-11-24 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
JPH04235974A (ja) 1990-06-08 1992-08-25 Roussel Uclaf 新規なイミダゾール誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
AU7820091A (en) 1990-06-08 1991-12-12 Roussel-Uclaf New benzimidazole derivatives, their preparation process, the new intermediates obtained, their use as medicaments and the pharmaceutical compositions containing them
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
WO1991019715A1 (en) 1990-06-15 1991-12-26 G.D. Searle & Co. 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
US5399566A (en) 1990-06-19 1995-03-21 Meiji Seika Kabushiki Kaisha Pyridine derivatives having angiotensin II antagonism
JPH05509086A (ja) 1990-06-22 1993-12-16 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー イミダゾールアンジオテンシン―２受容体拮抗薬による慢性腎不全の治療
NZ238688A (en) 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
IE912114A1 (en) 1990-07-02 1992-01-15 Union Pharma Scient Appl Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present
IL98319A (en) 1990-07-05 1997-04-15 Roussel Uclaf Sulphurous derivatives of imidazole, their preparation process, and pharmaceutical compositions containing them
US5137902A (en) 1990-07-13 1992-08-11 E. I. Du Pont De Nemours And Company 4-alkylimidazole derivatives and anti-hypertensive use thereof
CA2044806A1 (en) 1990-07-18 1992-01-19 Roland Jaunin Purine derivatives
CA2047029A1 (en) 1990-07-19 1992-01-20 Shieh-Shung T. Chen Microbial transformation process for antihypertensive products
DE4023215A1 (de) 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
RU1836357C (ru) 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами
NZ239161A (en) 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
EP0470543A1 (de) 1990-08-10 1992-02-12 Dr. Karl Thomae GmbH Heterocyclische Imidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zur ihrer Herstellung
US5217985A (en) 1990-08-28 1993-06-08 G. D. Searle & Co. Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension
AU8405691A (en) 1990-09-04 1992-03-30 Yamanouchi Pharmaceutical Co., Ltd. Novel tetrahydrobenzazole derivative
CA2048699A1 (en) * 1990-09-04 1992-03-05 Abraham Sudilovsky Method for preventing or treating cerebro-vascular disease employing ceronapril
IE912956A1 (en) 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
IL99372A0 (en) 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
US5140036A (en) 1990-09-19 1992-08-18 G. D. Searle & Co. 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5210092A (en) 1990-09-25 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Angiotensin ii antagonizing heterocyclic derivatives
US5242939A (en) 1990-09-28 1993-09-07 Warner-Lambert Company Anilide derivatives with angiotensin ii antagonist properties
EP0481614A1 (en) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
US5126342A (en) 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
CA2053148A1 (en) 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5470975A (en) * 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
US5430145A (en) 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2053340C (en) 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
WO1992007852A1 (en) 1990-10-25 1992-05-14 G.D. Searle & Co. Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders
AU636066B2 (en) 1990-10-30 1993-04-08 Takeda Chemical Industries Ltd. Thienoimidazole derivatives, their production and use
PH31175A (en) 1990-10-31 1998-03-20 Squibb & Sons Inc Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives.
US5087634A (en) 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
DE4036645A1 (de) 1990-11-16 1992-05-21 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, deren enthaltende mittel und deren verwendung
DE4036706A1 (de) 1990-11-17 1992-05-21 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
GB9025123D0 (en) 1990-11-19 1991-01-02 Ici Plc Nitrogen compounds
GB9026006D0 (en) 1990-11-29 1991-01-16 Glaxo Group Ltd Chemical compounds
EP0559755A1 (en) 1990-11-30 1993-09-15 Smithkline Beecham Corporation Substituted 5-aryl imidazoles
CA2057089A1 (en) 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
WO1992010189A1 (en) 1990-12-14 1992-06-25 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
AU657498B2 (en) 1990-12-14 1995-03-16 Novartis Ag Biphenylyl compounds
US5175180A (en) 1990-12-20 1992-12-29 G. D. Searle & Co. N-substituted n-(alpha-triazolyl-toluyl)pyrrole compounds and use for treatment of circulatory disorders
CA2058198A1 (en) 1991-01-04 1992-07-05 Adalbert Wagner Azole derivatives, process for their preparation, and their use
US5124335A (en) 1991-01-30 1992-06-23 Merck & Co., Inc. Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists
US5290780A (en) 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
AT395853B (de) 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
EP0498722B1 (fr) 1991-02-07 1997-07-30 Roussel Uclaf Dérivés bicycliques azotés, leur procédé de préparation, les intermédiaires obtenus, leur application comme médicaments et les compositions pharmaceutiques les renfermant
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
IE920175A1 (en) 1991-02-11 1992-08-12 Zeneca Ltd Nitrogen heterocycles
GB9102803D0 (en) 1991-02-11 1991-03-27 Ici Plc Pyridine compounds
GB9102804D0 (en) 1991-02-11 1991-03-27 Ici Plc Heterocyclic derivatives
IL100917A0 (en) 1991-02-16 1992-11-15 Fisons Plc Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
FR2672892B1 (fr) 1991-02-20 1994-01-14 Synthelabo Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
CA2061159A1 (en) 1991-02-26 1992-08-27 Michael A. Poss Imidazole and benzimidazole derivatives
FR2673427B1 (fr) 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
EP0503838A3 (en) 1991-03-08 1992-10-07 Merck & Co. Inc. Heterocyclic compounds bearing acidic functional groups as angiotensin ii antagonists
EP0505098A1 (en) 1991-03-19 1992-09-23 Merck & Co. Inc. Imidazole derivatives bearing acidic functional groups as angiotensin II antagonists
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5187179A (en) 1991-03-22 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole
US5128327A (en) 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
EP0505954A1 (en) 1991-03-25 1992-09-30 Glaxo Group Limited N-Imidazolylmethyl benzofuran derivatives as inhibitors of angiotensin II activity
US5177074A (en) 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
DE4110019C2 (de) 1991-03-27 2000-04-13 Merck Patent Gmbh Imidazopyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5164403A (en) 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
US5157040A (en) 1991-04-05 1992-10-20 Merck & Co., Inc. Substituted quinolines as angiotensin ii antagonists
US5151435A (en) 1991-04-08 1992-09-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating an indole or dihydroindole
US5155117A (en) 1991-04-12 1992-10-13 G. D. Searle & Co. 1-arylheteroarylalkyl substituted-1h-1,2,4-triazole compounds for treatment of circulatory disorders
TW274551B (sv) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
DE4200954A1 (de) 1991-04-26 1992-10-29 Bayer Ag Heterocyclisch substituierte phenylessigsaeurederivate
US5252574A (en) 1991-04-26 1993-10-12 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted thiophene or furan
CZ227093A3 (en) 1991-04-29 1994-03-16 Merck & Co Inc Mixture suitable for the preparation of tablets by direct moulding
GB9109246D0 (en) 1991-04-30 1991-06-19 Ici Plc Nitrogen derivatives
US5198438A (en) 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5162325A (en) 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
US5506361A (en) * 1991-05-08 1996-04-09 Theupjohn Company Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same
JPH05112533A (ja) 1991-05-08 1993-05-07 Upjohn Co:The イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5223501A (en) 1991-05-10 1993-06-29 Merck & Co., Inc. Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists
US5238942A (en) 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5162340A (en) 1991-05-10 1992-11-10 Merck & Co., Inc. Substituted 1-(2h)-isoquinolinones bearing acidic functional groups as angiotensin ii antagonists
GB9110532D0 (en) 1991-05-15 1991-07-03 Smithkline Beecham Corp Chemical compounds
GB9110623D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
GB9110625D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
JPH06211845A (ja) 1991-05-16 1994-08-02 Glaxo Group Ltd ベンゾフラン誘導体
GB9110635D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
KR920021542A (ko) 1991-05-16 1992-12-18 배리 안토니 뉴샘 벤조푸란 유도체
FR2676734B1 (fr) 1991-05-23 1995-05-19 Roussel Uclaf Nouveaux derives de la pyrimidine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant.
WO1992021666A1 (fr) 1991-05-31 1992-12-10 Laboratoires Upsa Derives de thiazole antagonistes de recepteurs a l'angiotensine ii
AU1625192A (en) 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
US5175164A (en) 1991-06-05 1992-12-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
JPH05213884A (ja) 1991-06-14 1993-08-24 Upjohn Co:The 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
US5210211A (en) 1991-06-21 1993-05-11 Warner-Lambert Company 4-(1h-pyrrol-1-yl) imidazoles with angiotension ii antagonist activity
GB9113626D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic compounds
GB9113628D0 (en) 1991-06-25 1991-08-14 Ici Plc Heterocyclic derivatives
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
WO1993001177A1 (en) 1991-07-03 1993-01-21 Merck & Co., Inc. Substituted triazolinones
FR2678618B1 (fr) 1991-07-05 1993-11-05 Upsa Laboratoires Nouveaux derives de triazolo pyrimidine antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
AU2338992A (en) 1991-07-26 1993-03-02 G.D. Searle & Co. Carbonate-substituted imidazo(4,5-d) pyridazine compounds for treatment of cardiovascular disorders
IT1250749B (it) 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
WO1993003040A1 (en) 1991-08-05 1993-02-18 Taisho Pharmaceutical Co., Ltd. Thienopyrimidin-4-one derivative
US5225401A (en) 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
US5246944A (en) 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
ATE152718T1 (de) 1991-08-15 1997-05-15 Ciba Geigy Ag N-acyl-n-heterocyclyl- oder naphthylalkyl- aminosäuren als angiotensin ii antagonisten
US5316051A (en) 1991-09-20 1994-05-31 L.G.L. Electronics S.P.A. Self-adjusting thread braking device for weft feeder units
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
CA2078759C (en) 1991-09-27 2003-09-16 Alan M. Warshawsky Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
AU657793B2 (en) 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
JPH06107661A (ja) * 1991-10-24 1994-04-19 Upjohn Co:The イミダゾール誘導体およびこれを有効成分とする医薬組成物
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US5977160A (en) * 1992-04-10 1999-11-02 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5552397A (en) 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
WO1993023403A1 (en) 1992-05-15 1993-11-25 Merrell Dow Pharmaceuticals Inc. NOVEL MERCAPTOACETYLAMIDO PYRIDAZO[1,2]PYRIDAZINE, PYRAZOLO[1,2]PYRIDAZINE, PYRIDAZO[1,2-a][1,2]DIAZEPINE AND PYRAZOLO[1,2-a][1,2]DIAZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE
WO1994002142A1 (en) * 1992-07-17 1994-02-03 Merck & Co., Inc. Substituted biphenylmethylimidazopyridines
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
US5504080A (en) 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
DE4308504A1 (de) * 1993-03-18 1994-09-22 Knoll Ag Neue Verwendung einer Kombination aus Verapamil und Trandolapril
DE4309553A1 (de) * 1993-03-24 1994-09-29 Bayer Ag Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
WO1994028901A1 (fr) 1993-06-11 1994-12-22 Eisai Co., Ltd. Derive aminoacide
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5362727A (en) 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5525723A (en) 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
ES2079315B1 (es) * 1994-02-24 1996-10-16 Uriach & Cia Sa J Nuevas imidazopiridinas.
ES2105939B1 (es) * 1994-08-02 1998-07-01 Uriach & Cia Sa J Nuevos pirazoles con actividad antagonista de la angiotensina ii.
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DK0808172T3 (da) * 1995-02-10 2003-10-20 Searle & Co Kombinationer af angiotensinkonverterende enzyminhibitor og bivirkningsreducerende mængde af aldesteronantagonist
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5656603A (en) * 1995-05-31 1997-08-12 Loyola University Of Chicago Aminopeptidase P inhibitors and uses thereof
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
GB2308064A (en) * 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
AU2252297A (en) * 1996-01-31 1997-08-22 Technology Licensing Co., L.L.C. Method of diagnosis and treatment and related compositions and apparatus
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
EP0910375B1 (en) * 1996-06-24 2002-05-02 Merck & Co., Inc. A composition of enalapril and losartan
WO1998030216A1 (en) * 1997-01-10 1998-07-16 Merck & Co., Inc. Use of angiotensin ii antagonists to treat symptomatic heart failure
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
PL197164B1 (pl) * 1997-10-17 2008-03-31 Ark Therapeutics Ltd Zastosowanie inhibitorów układu renina-angiotensyna
US6097772A (en) * 1997-11-24 2000-08-01 Ericsson Inc. System and method for detecting speech transmissions in the presence of control signaling
JPH11222439A (ja) * 1998-02-03 1999-08-17 Dainippon Pharmaceut Co Ltd 脳血管攣縮抑制薬
ZA991706B (en) * 1998-03-04 2000-10-03 Takeda Chemical Industries Ltd Sustained-release preparation for Aii Antagonist, production and use thereof.
CA2336822C (en) * 1998-07-10 2009-11-17 Novartis Ag Method of treatment and pharmaceutical composition
DE19913528A1 (de) * 1998-12-21 2000-06-29 Sanol Arznei Schwarz Gmbh Neue Verwendung von Moexipril
AU5016200A (en) * 1999-05-21 2000-12-12 Myriad Genetics, Inc. Diabetes gene
RU2276997C2 (ru) * 1999-08-30 2006-05-27 Санофи-Авентис Дойчланд Гмбх Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
PL370270A1 (en) * 2001-11-23 2005-05-16 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
ITBO20030050A1 (it) * 2003-02-06 2004-08-07 Ima Spa Macchina per il trattamento di prodotti farmaceutici.

Also Published As

Publication number Publication date
CN1384756A (zh) 2002-12-11
RU2272651C2 (ru) 2006-03-27
SI1925303T1 (sl) 2015-01-30
HUP0202461A3 (en) 2003-04-28
CZ2002644A3 (cs) 2002-05-15
EE05130B1 (et) 2009-02-16
US20110263619A1 (en) 2011-10-27
ATE554761T1 (de) 2012-05-15
JP2003508426A (ja) 2003-03-04
US20100267798A1 (en) 2010-10-21
JP4843172B2 (ja) 2011-12-21
IL148126A (en) 2014-12-31
WO2001015673A3 (en) 2002-03-07
SI1437131T1 (sl) 2012-09-28
CY1112987T1 (el) 2016-04-13
CN101537181A (zh) 2009-09-23
EP1437131B1 (en) 2012-04-25
SI1212081T2 (sl) 2014-08-29
CA2382387C (en) 2005-06-21
HK1050327A1 (en) 2003-06-20
TR200200518T2 (tr) 2002-06-21
ME00181B (me) 2010-10-10
CA2382387A1 (en) 2001-03-08
NO20020850D0 (no) 2002-02-21
DE60023518T2 (de) 2006-07-06
SI1212081T1 (sl) 2006-06-30
US20060194868A1 (en) 2006-08-31
NO329245B1 (no) 2010-09-20
AU2005203694A1 (en) 2005-09-08
YU3602A (sh) 2004-12-31
MEP28208A (en) 2010-10-10
MXPA02001633A (es) 2002-08-06
EP1212081B1 (en) 2005-10-26
EP2277519A3 (en) 2011-09-07
EP1212081A2 (en) 2002-06-12
EE200200085A (et) 2003-04-15
EP2277519A2 (en) 2011-01-26
RU2005128124A (ru) 2007-03-20
CN100408093C (zh) 2008-08-06
US20130317047A1 (en) 2013-11-28
HUP0202461A2 (hu) 2002-12-28
RU2002107673A (ru) 2004-01-10
EP1437131A1 (en) 2004-07-14
AU7648400A (en) 2001-03-26
EP1212081B8 (en) 2005-12-28
TR200202464T2 (tr) 2003-01-21
RS52907B (en) 2014-02-28
UA76702C2 (uk) 2006-09-15
TR200202467T2 (tr) 2002-12-23
DK1212081T3 (da) 2006-01-16
AU2009200551B2 (en) 2010-09-30
EP1925303B1 (en) 2014-09-24
EP1925303A3 (en) 2010-12-08
DK1212081T4 (da) 2014-07-07
KR20020060167A (ko) 2002-07-16
HRP20020169A2 (en) 2005-10-31
BR0013540A (pt) 2002-04-30
ES2250192T3 (es) 2006-04-16
IL148126A0 (en) 2002-09-12
TR200202463T2 (tr) 2003-01-21
TR200202466T2 (tr) 2002-12-23
UA88270C2 (ru) 2009-10-12
US20090258919A1 (en) 2009-10-15
DK1925303T3 (en) 2015-01-05
ZA200201471B (en) 2003-05-28
NO20020850L (no) 2002-02-21
ES2525699T3 (es) 2014-12-29
DK1437131T3 (da) 2012-08-06
SK2702002A3 (en) 2002-09-10
EP1925303A2 (en) 2008-05-28
CY1115869T1 (el) 2017-01-25
PT1925303E (pt) 2014-12-18
ATE307604T1 (de) 2005-11-15
RU2378018C2 (ru) 2010-01-10
BG106319A (bg) 2002-12-29
BG66115B1 (bg) 2011-05-31
CZ303433B6 (cs) 2012-09-12
NO20100569L (no) 2002-02-21
BG110479A (en) 2010-01-29
US20080125472A1 (en) 2008-05-29
PL353066A1 (en) 2003-10-06
ES2386141T3 (es) 2012-08-10
DE60023518T3 (de) 2014-08-28
HU229107B1 (en) 2013-07-29
SK288239B6 (sk) 2015-02-03
EP1212081B2 (en) 2014-04-02
ES2250192T5 (es) 2014-06-27
AU2009200551A1 (en) 2009-03-05
PT1437131E (pt) 2012-07-12
KR20080035703A (ko) 2008-04-23
DE60023518D1 (de) 2005-12-01
WO2001015673A2 (en) 2001-03-08
NZ571901A (en) 2010-05-28

Similar Documents

Publication Publication Date Title
SE9903028D0 (sv) New use
EE05670B1 (et) Ramipriil kardiovaskulaarsete haigusjuhtude „rahoidmiseks
WO2003020202A3 (en) Method for reducing hypertension and heart failure
WO2001082919A3 (en) Methods of and compounds for inhibiting calpains
Whelton et al. Once‐daily lisinopril compared with twice‐daily captopril in the treatment of mild to moderate hypertension: Assessment of office and ambulatory blood pressures
WO2002056837A3 (en) Inhibition of protein-phosphatases for the treatment of heart failure
Kopecky Idiopathic atrial fibrillation: prevalence, course, treatment, and prognosis
WO2003032963A3 (en) Method of reducing type 2 diabetes in high risk patients
Fariello et al. A004: Candesartan, ABPM and structural--functional parameters in essential hypertensive patients
HUP0303836A2 (hu) Angiotenzin antagonisták és ACE inhibitorok gyógyszerészeti kombinációja és ezeket tartalmazó gyógyszerkészítmények
NO20013753L (no) Anvendelse av moxonidin til behandling etter hjerteinfarkt
Bankhead Antihypertensive therapy: friend or foe in stroke?
WO2004075893A8 (en) Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker
Stergiou et al. A005: Additive hypotensive effect of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in essential hypertension
UA37953A (uk) Спосіб поліхіміотерапії вперше виявлених хворих деструктивним туберкульозом легень
OTSUKA et al. A Case of Angioneurotic Edema of the Tongue and Oral Floor Associated with Angiotensin-Converting Enzyme Inhibitor
Bakris Is ethnicity a factor in choice of antihypertensive drug?